These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28065355)

  • 1. Response to "Letter to the Editor Concerning the Paper by Fung et al titled 'Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women".
    Fung R; Lega I
    J Sex Med; 2017 Jan; 14(1):173-174. PubMed ID: 28065355
    [No Abstract]   [Full Text] [Related]  

  • 2. Concerning the Article by Fung et al, Titled "Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women".
    Defreyne J; T'Sjoen G
    J Sex Med; 2017 Jan; 14(1):172-173. PubMed ID: 28065354
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
    Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
    J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
    Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
    J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Cyproterone Acetate Treatment for Transgender Women.
    Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y
    J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogens and hirsutism.
    Biffignandi P; Molinatti GM
    Horm Res; 1987; 28(2-4):242-9. PubMed ID: 2969862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
    Spona J; Huber J; Schmidt JB
    Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cyproterone acetate (CPA) on serum lipoproteins when administered alone and in combination with ethinyl estradiol (EE).
    Lindberg UB; Crona N; Enk L; Samsioe G; Silfverstolpe G
    Horm Metab Res; 1987 May; 19(5):222-5. PubMed ID: 2953663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE.
    Bisson JR; Chan KJ; Safer JD
    Endocr Pract; 2018 Jul; 24(7):646-651. PubMed ID: 29708436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
    Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
    J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy.
    Martinez-Martin FJ; Kuzior A; Hernandez-Lazaro A; de Leon-Durango RJ; Rios-Gomez C; Santana-Ojeda B; Perez-Rivero JM; Fernandez-Trujillo-Comenge PM; Gonzalez-Diaz P; Arnas-Leon C; Acosta-Calero C; Perdomo-Herrera E; Tocino-Hernandez AL; Del Sol Sanchez-Bacaicoa M; Del Pino Perez-Garcia M
    Hypertens Res; 2023 Jan; 46(1):219-225. PubMed ID: 36229533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of antiandrogens and feminization in transgender women.
    Angus LM; Nolan BJ; Zajac JD; Cheung AS
    Clin Endocrinol (Oxf); 2021 May; 94(5):743-752. PubMed ID: 32926454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment.
    Defreyne J; Nota N; Pereira C; Schreiner T; Fisher AD; den Heijer M; T'Sjoen G
    LGBT Health; 2017 Oct; 4(5):328-336. PubMed ID: 28880825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic alternatives for the hirsute woman.
    Bassaw B; Maharaj R; Ali A; Roopnarinesingh S
    West Indian Med J; 1992 Mar; 41(1):12-4. PubMed ID: 1533080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.
    Nota NM; Dekker MJHJ; Klaver M; Wiepjes CM; van Trotsenburg MA; Heijboer AC; den Heijer M
    Andrologia; 2017 Aug; 49(6):. PubMed ID: 27561756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
    Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
    J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
    Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
    Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.